Safety concerns hang over new Alzheimer's treatment

Posted on AllSides November 29th, 2022
From The Center
Shoshana Gordon/Axios

Within hours, the world will have a better idea about prospects a new Alzheimer's treatment when Japanese drugmaker Eisai releases late-stage clinical trial results.

The big picture: News of a second patient death linked to the drug has dampened expectations and potentially created a more complicated path for the drug hitting the market.

Driving the news: Researchers will present the clinical trial results for Eisai and its partner Biogen's drug lecanemab this evening at the Clinical Trials on Alzheimer’s Disease conference in San Francisco.

Eisai shares fell by 6% on Tuesday after Science reported that a...

Read full story

Axios

AllSides Media Bias Rating: Center
AllSides Media Bias Rating: Center
111520/86501
See full bias rating for Axios
Learn about media bias
https://www.axios.com/2022/11/29/alzheimers-treatment-fda-safety-deaths

More News about Healthcare from the Left, Center and Right

From the Left

From the Center

From the Right